Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | PNMT | P11086 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15849014 | 0.85 | CYP3A4 (0.48) | PNMTPDE2ALMNATP53HTT | |
| SCHEMBL18075635 | 0.84 | PDE2A (0.51) | CYP1A2CYP2A6PNMTPDE2ALMNA | |
| SCHEMBL18103191 | 0.84 | PNMT (0.39) | CYP1A2CYP2A6PNMTPDE2ALMNA | |
| SCHEMBL24685760 | 0.84 | PNMT (0.39) | CYP1A2CYP2A6PNMTPDE2ALMNA | |
| SCHEMBL21180447 | 0.84 | LMNA (0.60) | CYP1A2CYP2A6PNMTPDE2ALMNA | |
| SCHEMBL14948883 | 0.83 | CYP1A2 (0.42) | CYP1A2CYP2A6PNMTLMNATP53 | |
| SCHEMBL17540835 | 0.82 | CSNK2A1 (0.56) | PNMTLMNATP53HTTCSNK2A1 | |
| SCHEMBL16955282 | 0.82 | THRB (0.47) | PNMTPDE2ALMNATP53HTT | |
| SCHEMBL15617289 | 0.82 | PNMT (0.40) | CYP1A2PNMTPDE2ALMNATP53 | |
| SCHEMBL11865637 | 0.82 | PNMT (0.48) | PNMTLMNATP53HTTCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024059665-A1 | DIMERIC COMPOUNDS AS INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-11834440-B2 | Beta-lactam derivatives for the treatment of diseases | INSILICO MEDICINE IP LIMITED (HK) | 2023-12-05 | — | — | US | disclosed |
| US-11802127-B2 | 3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors | PFIZER INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-11691973-B2 | 3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors | PFIZER INC. (US) | 2023-07-04 | — | — | US | disclosed |
| WO-2022208391-A1 | 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS | PFIZER INC, (US) | 2022-10-06 | — | — | WO | disclosed |
| US-20120165320-A1 | NOVEL AZABICYCLOHEXANES | PANACEA BIOTEC LTD. (IN) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691973-B2 | 3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors | NRAS, KRAS, MAPK1 | CYP1A2 654/4885CYP2A6 2084/4885PNMT 1874/4885 |
| US-20120165320-A1 | NOVEL AZABICYCLOHEXANES | CYP3A43, UGT1A1, CYP3A4 | CYP1A2 12/4885CYP2A6 41/4885PNMT 2601/4885 |
| US-11834440-B2 | Beta-lactam derivatives for the treatment of diseases | QPCT, QPCTL, BCAT1 | CYP1A2 3521/4885CYP2A6 2842/4885PNMT 1844/4885 |
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | CYP1A2 486/4885CYP2A6 506/4885PNMT 3421/4885 |
| US-11802127-B2 | 3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors | NRAS, KRAS, MAPK1 | CYP1A2 654/4885CYP2A6 2084/4885PNMT 1874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.